Theriva Biologics (NYSEAMERICAN:TOVX) Releases Earnings Results

Theriva Biologics (NYSEAMERICAN:TOVX) announced its earnings results on Tuesday. The company reported ($0.30) EPS for the quarter, reports.

Theriva Biologics Trading Up 0.2 %

Shares of NYSEAMERICAN:TOVX traded up $0.00 during mid-day trading on Friday, reaching $0.40. 71,519 shares of the company traded hands, compared to its average volume of 125,929. Theriva Biologics has a 52 week low of $0.20 and a 52 week high of $1.20. The company has a market cap of $7.00 million, a PE ratio of -0.35 and a beta of 1.48.

Theriva Biologics Company Profile

Theriva Biologics, Inc, a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors.